Bridgewater Chapter Upcoming Events Join PCCI


Chronic Airway Therapeutics (CAT)

Next steps for heart failure drug



Presenter: Mitchell Glass


Monday, February 18, 2019

Embassy Suites, Chesterbrook, Pennsylvania (directions)




China estimates more than 50 million patients may have chronic obstructive pulmonary disease (COPD), due to to serious air pollution and a high rate of cigarette smoking. Authorities have identified COPD as a critical area of medical need.


Chronic Airway Therapeutics (CAT) owners, Hong Kong based Cho Group, are driving Chinese development of its first product, oral nadolol, a well-established cardiac beta blocker,  as a treatment for COPD.  CAT, now a US based stand-alone entity, will orchestrate that development, then pursue US registration for other indications.  Two inhalable products will follow.


Nadolol, unlike existing treatments – can be administered in a single tablet per day.  It is expected to play an integral role in managing COPD, which  describes various long-term lung diseases that cause shortness of breath, including emphysema and chronic bronchitis.


CAT has begun the regulatory process with pre-IND meetings with the Chinese National Medical Products Administration (NMPA), the agency comparable to the FDA.  CAT has received comment from the NMDA recommending a small Phase II study prior to progressing to Phase III, insisting on local manufacture for Phase III. CAT is exploring broader relations with clinical research organizations familiar with both Chinese and US regulatory requirements.



3 Major Issues


  1. Our principal investors are in Hong Kong.  The NMDA (Chinese FDA), has accepted our plan to move to Phase III trials in China.  What benefits and risks should we be looking for in doing development in China first?  This could include dealing with investors, contracted services providers and the NMDA.  Does this help or hinder development in the US?
  2.  Interest among KOLs is outstanding.  Despite high interest, kind words and few objections among investors, locking their commitment in China and the US has been slow. What do we need to do to get them over the hump?
  3. We have full rights and authority to fund and build the US business.  Investors in Hong Kong are solely focused on China.  How might we better target investors who will fund 505(b)(2) product development in the US?





6:30 - Cocktails & Dinner (Cash bar and special 2-entree buffet menu)

7:45 - Mitchell Glass, CEO and Managing Director of CAT, will deliver "Elevator" Pitch to the Group

8:00 - A Panel will address three major issues crucial to helping the Company reach the next level.

9:00 - Open discussion: members and guests




Available Media

Please note: All information obtained here is the property of those presenting and should not be copied or duplicated without written consent.



None available at this time


None available at this time


None available at this time


Chronic Airway Therapeutics
webcast 02/18/2019


The webcast recording of the PCCI meeting is posted on the PCCI website a few days after the event.

Contact Info:



Our Sponsors

EisnerAmperGlaxoSmithKlineKEH Insurance Agency
New Jersey Institute of Technology
Science CenterWhite and Williams


<Top of the page>





Questions or Coments?

Contact: Peter van der Kam, | (610) 296-8086




Good Company! Good Drink! Good Food! Good Program! Good Fun!


Site Navigation



Pharmaceutical Consulting Consortium International, Inc., or (610) 296-8086

Meetings Held at Embassy Suites - Valley Forge

888 Chesterbrook Blvd, Chesterbrook, Pennsylvania 19087

All content on this website is copyrighted and should not be reproduced without the consent of PCCI.

© Copyright 2016-2018



Tat Communication Inc